An observational study in Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG) and Dry Eye Disease (DED), sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 20 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Massachusetts General Hospital · Observational
The overall goal of this study is to develop Brillouin microscope as a novel tool for measuring biomechanical and hydration properties of human tissues in vivo.
Our long-term goal is to establish a direct, accurate, and clinically viable method for measuring corneal hydration, enabling earlier detection, more precise diagnosis, and improved management of corneal diseases and postoperative complications. The objective of this study is to develop and validate Brillouin based hydration mapping as a diagnostic tool to quantify water content in the cornea across healthy individuals and patients with diverse ocular conditions. Our central hypothesis is that spatially resolved Brillouin frequency shifts can reveal disease-specific hydration profiles that are not detectable through conventional thickness-based methods. This hypothesis is based on recent evidence from our group demonstrating that Brillouin microscopy is sensitive to hydration. The rationale for this research is that Brillouin-based hydration maps will offer an unprecedented, morphology-independent metric of corneal fluid balance, which could improve clinical decision-making in a range of pathologies.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.
This study's planned enrollment of 90 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.
Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Aim 1 - Control Group (Healthy Subjects) : 10 subjects per 6 age ranges (20-29yr, 30-39yr, 40-49yr, 50-59yr, 60-69yr, 70-79yr), total 60 subjects
Aim 2 - Patient Groups : 20 patients per 6 diseases (Moderate Fuchs' endothelial dystrophy, Early-stage isolated corneal guttae, Primary open-angle glaucoma, Dry eye disease, Keratoconus, post-LASIK), total 120 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Healthy Subjects
Patient Subjects (Fuch's endothelial dystrophy, Corneal guttae, Open-angle glaucoma, Dry eye disease, Keratoconus, post-LASIK)
Number of subjects to successfully complete Brillouin measurement without serious unanticipated adverse events related to application of the device.
Number and percentage of enrolled subjects who complete the single Brillouin imaging session without experiencing a serious unanticipated adverse event related to the investigational Brillouin Ocular Scanner, as determined by study staff monitoring during and immediately following the imaging procedure.
Time frame: Through completion of the single study visit, approximately 1-2 hours
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →